The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in adults with alkaptonuria, Cycle Pharmaceuticals announced on Thursday. Alkaptonuria is an ultra-rare ...

A new study has identified the drug that treats the extremely rare genetic disease alkaptonuria (AKU). A new study published in Molecular Genetics and Metabolism, conducted by a Liverpool based ...

Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) in adult patients with AKU.1 The approval of HARLIKU is based ...

Following the written consultation on the draft remit and scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the September 2020 ...

A drug named nitisinone was found to stop the progression of the extremely rare genetic disease alkaptonuria (AKU)also known as black bone disease, revealed study carried out by Liverpool researchers ...

Alkaptonuria, caused by mutations in the HGO gene and a deficiency of homogentisate 1,2-dioxygenase, results in an accumulation of homogentisic acid (HGA), ochronosis, and destruction of connective ...

Alkaptonuria is a rare, autosomal recessive metabolic disorder arising from the deficiency of the enzyme homogentisate 1,2-dioxygenase, which disrupts the normal degradation of tyrosine. This ...

In the fight against malaria, controlling the mosquito population is crucial. Several methods are currently used to reduce mosquito numbers and malaria risk. One of these includes the antiparasitic ...

In the fight against malaria, controlling the mosquito population is crucial. Several methods are currently used to reduce mosquito numbers and malaria risk. One of these includes the antiparasitic ...

BOSTON & CAMBRIDGE, England, June 19, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) ...

BOSTON, July 17, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals announced the launch of HARLIKU, the first and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients ...